In a significant advancement in cancer research, scientists at the University of California, Los Angeles (UCLA) have developed a novel cell-based immunotherapy aimed at treating pancreatic cancer. This breakthrough was reported in research that involved preclinical studies conducted on mice. The innovative treatment designed to track and eliminate pancreatic tumors demonstrated positive results by successfully slowing cancer growth, prolonging survival rates, and maintaining effectiveness even within challenging tumor environments.
One notable aspect of this therapy is its ability to target cancerous cells that have metastasized to other organs, such as the liver and lungs. This was achieved by utilizing CAR-NKT (chimeric antigen receptor natural killer T) cells that effectively infiltrated the tumor rather than remaining on the outer edges, which is a common issue with many current immune treatments. The engineered immune cells leveraged multiple methods to identify and destroy cancer cells, showcasing their adaptability against varying cancer cell characteristics.
Financial considerations also play a role in this innovation, as the estimated cost for a single treatment dose stands at approximately $5,000, significantly lower than the costs associated with personalized CAR-T (chimeric antigen receptor T-cell) therapies. Moreover, one donor's cells could potentially provide enough for thousands of different patients, making this approach more affordable and accessible. This is particularly significant given that the therapy targets a protein commonly found in various types of cancers, including breast, ovarian, and lung cancers, thereby potentially offering a multi-cancer treatment option.
As the research team prepares to submit applications to the Food and Drug Administration (FDA) for approval to begin human clinical trials, the path ahead holds promise. However, the researchers acknowledged the complexities associated with human tumors, which evolve and can lose target recognition, presenting unique challenges. They highlight the importance of producing reliable batches of identical and safe cells, which also involves navigating logistical and regulatory hurdles. While these potential therapies mark a crucial step in cancer treatment, long-term effects and safety in human subjects remain undefined until comprehensive clinical trials are conducted.
